Partner Fund Management L.P. trimmed its position in shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 17.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,258,443 shares of the company’s stock after selling 461,775 shares during the quarter. Aerie Pharmaceuticals makes up 2.0% of Partner Fund Management L.P.’s portfolio, making the stock its 6th biggest holding. Partner Fund Management L.P. owned 4.97% of Aerie Pharmaceuticals worth $139,007,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. BlackRock Inc. boosted its position in Aerie Pharmaceuticals by 4.5% during the third quarter. BlackRock Inc. now owns 3,124,340 shares of the company’s stock worth $192,304,000 after purchasing an additional 133,239 shares in the last quarter. Jennison Associates LLC boosted its position in Aerie Pharmaceuticals by 5.8% during the third quarter. Jennison Associates LLC now owns 1,386,211 shares of the company’s stock worth $85,321,000 after purchasing an additional 76,390 shares in the last quarter. FMR LLC boosted its position in Aerie Pharmaceuticals by 25.4% during the second quarter. FMR LLC now owns 1,095,652 shares of the company’s stock worth $74,011,000 after purchasing an additional 221,582 shares in the last quarter. Columbus Circle Investors boosted its position in Aerie Pharmaceuticals by 3.1% during the third quarter. Columbus Circle Investors now owns 798,376 shares of the company’s stock worth $49,140,000 after purchasing an additional 24,196 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in Aerie Pharmaceuticals by 5.5% during the second quarter. Bank of New York Mellon Corp now owns 630,612 shares of the company’s stock worth $42,597,000 after purchasing an additional 32,820 shares in the last quarter.

In other news, CFO Richard J. Rubino sold 66,605 shares of the business’s stock in a transaction on Thursday, September 27th. The stock was sold at an average price of $60.23, for a total value of $4,011,619.15. Following the completion of the transaction, the chief financial officer now directly owns 334,236 shares of the company’s stock, valued at $20,131,034.28. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Casey C. Kopczynski sold 11,000 shares of the business’s stock in a transaction on Monday, December 3rd. The stock was sold at an average price of $39.81, for a total value of $437,910.00. Following the completion of the transaction, the insider now directly owns 118,042 shares of the company’s stock, valued at $4,699,252.02. The disclosure for this sale can be found here. Over the last three months, insiders sold 134,117 shares of company stock valued at $7,784,846. Insiders own 10.53% of the company’s stock.

AERI has been the topic of a number of research analyst reports. ValuEngine downgraded Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, November 27th. BidaskClub downgraded Aerie Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 7th. Cowen boosted their target price on Aerie Pharmaceuticals from $100.00 to $105.00 and gave the stock a “buy” rating in a research report on Thursday, August 9th. Zacks Investment Research downgraded Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 9th. Finally, Stifel Nicolaus boosted their target price on Aerie Pharmaceuticals from $80.00 to $87.00 and gave the stock a “buy” rating in a research report on Tuesday, September 11th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and eleven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $79.25.

NASDAQ AERI opened at $40.87 on Wednesday. Aerie Pharmaceuticals Inc has a fifty-two week low of $38.50 and a fifty-two week high of $74.75. The firm has a market capitalization of $1.81 billion, a PE ratio of -12.13 and a beta of 0.92.

Aerie Pharmaceuticals (NASDAQ:AERI) last released its quarterly earnings results on Tuesday, November 6th. The company reported ($1.73) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.33) by ($0.40). The firm had revenue of $7.30 million during the quarter, compared to the consensus estimate of $5.63 million. Equities research analysts anticipate that Aerie Pharmaceuticals Inc will post -5.48 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.watchlistnews.com/aerie-pharmaceuticals-inc-aeri-is-partner-fund-management-l-p-s-6th-largest-position/2662634.html.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Featured Story: How to invest in a bear market

Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals Inc (NASDAQ:AERI).

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.